Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Treasury Shares (2018 - 2025)

Bicycle Therapeutics (BCYC) has disclosed Treasury Shares for 5 consecutive years, with $1.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Treasury Shares rose 118.3% year-over-year to $1.7 million, compared with a TTM value of $1.7 million through Sep 2025, up 118.3%, and an annual FY2024 reading of $674262.0, up 106.29% over the prior year.
  • Treasury Shares was $1.7 million for Q3 2025 at Bicycle Therapeutics, down from $1.8 million in the prior quarter.
  • Across five years, Treasury Shares topped out at $1.9 million in Q1 2025 and bottomed at $187725.0 in Q1 2022.
  • Average Treasury Shares over 4 years is $721910.7, with a median of $452576.0 recorded in 2023.
  • Peak annual rise in Treasury Shares hit 141.08% in 2023, while the deepest fall reached 74.11% in 2023.
  • Year by year, Treasury Shares stood at $187725.0 in 2022, then soared by 74.11% to $326848.0 in 2023, then skyrocketed by 106.29% to $674262.0 in 2024, then surged by 152.83% to $1.7 million in 2025.
  • Business Quant data shows Treasury Shares for BCYC at $1.7 million in Q3 2025, $1.8 million in Q2 2025, and $1.9 million in Q1 2025.